DBV Technologies Achieves Positive Results for Viaskin Peanut Patch in Children
DBV Technologies has announced promising preliminary results for the phase 3 VITESSE study, evaluating the Viaskin Peanut patch in children aged 4 to 7 years with peanut allergies.
Successful Primary Endpoint Achievement in Phase 3 Trial
DBV Technologies, listed on Euronext and Nasdaq, reported that the VITESSE phase 3 clinical trial met its primary endpoint for the Viaskin Peanut patch. After 12 months, 46.6% of the children treated with Viaskin Peanut showed a favorable response compared to 14.8% in the placebo group. The difference in response between the groups was 31.8% with a 95% confidence interval ranging from 24.5 to 39.0%, exceeding the predefined threshold of 15%.
Study Details and Safety Outcomes
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The study included 654 children, with 438 in the active group and 216 in the placebo group. Safety results were consistent with previous profiles, with mild to moderate adverse events primarily being skin reactions. The discontinuation rate due to these events was 3.2% in the active group and 0.5% in the placebo group.
Future Plans and Financial Position Strengthening
DBV Technologies plans to file for a Biologics License Application in the United States by the first half of 2026. The announcement of these results has triggered financing conditions, allowing the exercise of shares and warrants until January 15, 2026, thereby strengthening the company's financial position.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
